|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study显示文摘The outcome of hepatocellular carcinoma(HCC) patients significantly differs between western and eastern population centers. Our group previously developed and validated the Chinese University Prognostic Index(CUPI) for the prognostication of HCC among the Asian HCC patient population. In the current study, we aimed to validate the CUPI using an international cohort of patients with HCC and to compare the CUPI to two widely used staging systems, the Barcelona Clinic Liver Cancer(BCLC) classification and the Cancer of the Liver Italian Program(CLIP). To accomplish this goal, two cohorts of patients were enrolled in the United Kingdom(UK; n = 567; 2006-2011) and Hong Kong(HK; n = 517; 2007-2012). The baseline clinical data were recorded. The performances of the CUPI, BCLC, and CLIP were compared in terms of a concordance index(C-index) and were evaluated in subgroups of patients according to treatment intent. The results revealed that the median follow-up durations of the UK and HK cohorts were 27.9 and 29.8 months, respectively. The median overall survival of the UK and HK cohorts were 22.9 and 8.6 months, respectively. The CUPI stratified the patients in both cohorts into three risk subgroups corresponding to distinct outcomes. The median overall survival of the CUPI low-, intermediate-, and high-risk subgroups were 3.15, 1.24, and 0.29 years, respectively, in the UK cohort and were 2.07, 0.32, and 0.10 years, respectively, in the HK cohort. For the patients who underwent curative treatment, the prognostic performance did not differ between the three staging systems, and all were suboptimal. For those who underwent palliative treatment, the CUPI displayed the highest C-index, indicating that this staging system was the most informative for both cohorts. In conclusion, the CUPI is applicable to both western and eastern HCC patient populations. The performances of the three staging systems differed according to treatment intent, and the CUPI was demonstrated to be optimal for those undergoing palliative treatment. A more precise staging system for early-stage disease patients is required. | Stephen L.Chan Philip J.Johnson Frankie Mo Sarah Berhane Mabel Teng Anthony W.H.Chan Ming C.Poon Paul B.S.Lai Simon Yu Anthony T.C.Chan Winnie Yeo | 2014 | Chinese Journal of Cancer2014，33，10： | 4 |
| 2 | Systemic treatment for inoperable pancreatic adenocarcinoma: review and update显示文摘There have been many clinical trials conducted to evaluate novel systemic regimens for unresectable pancreatic cancer. However, most of the trial results were negative, and gemcitabine monotherapy has remained the standard systemic treatment for years. A number of molecular targeted agents, including those against epidermal growth factor receptor and vascular endothelial growth factor receptors, have also been tested. In recent years, there have been some breakthroughs in the deadlock: three regimens, namely gemcitabine-erlotinib, FOLFIRINOX, and gemcitabine-nab-paclitaxel, have been shown to prolong the overall survival of patients when compared with gemcitabine monotherapy. In addition, emerging data suggested that the membrane protein human equilibrative nucleotide transporter 1 is a potential biomarker with which to predict the efficacy of gemcitabine. Here we review the literature on the development of systemic agents for pancreatic cancer, discuss the current choices of treatment, and provide future directions on the development of novel agents. | Stephen L.Chan Sin T.Chan Eric H.Chan Zhe-Xi He | 2014 | Chinese Journal of Cancer2014，33，6： | 2 |
| 3 | Cancer risk in collagenous colitis显示文摘 | Jean L.Chan Anne C.Tersmette G. Johan A.Offerhaus Stephen B.Gruber Theodore M.Bayless Francis M.Giardiello | 2007 | Inflamm Bowel Dis2007，，1： | 1 |
| 4 | The Hong Kong consensus statements on unresectable hepatocellular carcinoma:narrative review and update for 2021显示文摘Background and Objective:Hong Kong,like many parts of Asia,faces a high burden of hepatocellular carcinoma(HCC)caused by high endemic rates of hepatitis B virus infection.Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical,transarterial,ablative,radiotherapeutic and systemic modalities.This publication summarizes the latest evidence-based recommendations on how these modalities should be used.Methods:In two meetings held in 2020,a multidisciplinary panel of surgeons,oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC,with an emphasis on treatment of HCC not amenable to surgical resection.Close attention was paid to new evidence published since the previous version of these statements in 2018.Key Content and Findings:The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC.Since the previous version of these statements,considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence.Conclusions:Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection.In particular,there is a need for more evidence to aid physicians in the selection of second-line systemic therapies,as currently most data are limited to patients with disease progression on first-line sorafenib. | Tan-To Cheung Simon Chun-Ho Yu Stephen L.Chan Ronnie T.P.Poon Philip Kwok Ann-Shing Lee Anna Tai Derek Tam Chin-Cheung Cheung Tak-Wing Lai Nam-Hung Chia Ada Law Tracy Shum Yim-Kwan Lam Vince Lau Victor Lee Charing Chong Chung-Ngai Tang Thomas Yau | 2023 | Hepatobiliary Surgery and Nutrition2023，12，3： | 0 |
| 5 | What do oncologists need to know about biosimilar products?显示文摘Many biologic products have improved the outcomes of cancer patients,but the costs can substantially burden healthcare systems.Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.Approval of a biosimilar product relies on the demonstration of 'comparability' or 'no clinically meaningful differences' as compared to its reference biologic product.Biosimilar products for erythropoietin,granulocyte colonystimulating factor,trastuzumab,and rituximab are already available,and the regulatory processes in various countries are constantly evolving.It is important that oncologists be familiar with the potential issues surrounding the clinical use of biosimilar products.In this review article,we provide background information about biosimilar products and their regulatory approval processes,followed by a discussion of individual biosimilar drugs. | Linda K.S.Leung Kevin Mok Calvin Liu Stephen L.Chan | 2016 | Chinese Journal of Cancer2016，35，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员